China Pharmaceutical Achieves Major Success: 4 Injectable Drugs Approved on the Same Day
Source: Dengyuemed | September 12, 2025 | Category: Pharmaceuticals
As a Hong Kong drug wholesale distributor, we stay open to learning and closely track China’s progress in injectable drugs and other new approvals, helping us anticipate trends and deliver timely, high-quality solutions for patients and partners.
Recently, the official website of the National Medical Products Administration (NMPA) announced that China Pharmaceutical had four injectable drugs approved for production on the same day, with the approvals considered as passing the consistency evaluation.
These injectable drugs are: Levofloxacin Injectable Drug, Morpholine Nitroimidazole Sodium Chloride Injectable Drug, Structured Lipid Emulsion Injectable Drug (C6-24), and Long-Chain Lipid Emulsion Injectable Drug (OO).
So far this year, China Pharmaceutical has had 38 products approved for production and considered as passing the consistency evaluation, including one biosimilar approved as the first domestic launch, and two Class 1 new drugs approved for new indications.
Levofloxacin and Morpholine Nitroimidazole Sodium Chloride are both anti-infective drugs. Among them, Levofloxacin Injectable Drug is a quinolone antibacterial drug, and in 2024, its sales in China’s three major terminals across six major markets grew by more than 1,200%.
Morpholine Nitroimidazole Sodium Chloride Injectable Drug is a Class 1.1 new drug originally approved in 2014. Currently, multiple generics have been approved and launched.
Structured Lipid Emulsion Injectable Drug (C6-24) and Long-Chain Lipid Emulsion Injectable Drug (OO) are parenteral nutrition drugs.
These drugs play a vital role in the treatment of critically ill patients and those with severe trauma, providing rapid nutritional support, promoting patient recovery, and improving disease prognosis.
Currently, China Pharmaceutical has more than 10 parenteral nutrition injectable drugs approved for marketing, covering single-bag (vial), dual-chamber bag, and three-chamber bag formulations.
According to data, this year, China Pharmaceutical (excluding joint ventures) has had 38 products approved for production and considered as passing the consistency evaluation, mainly in therapeutic areas such as blood and hematopoietic system drugs (10 products), systemic anti-infectives (7 products), and digestive system and metabolic drugs (7 products).
Among these 38 products, several are the first domestic launches. These include Luqubopapa Tablets, Imipenem/Cilastatin Sodium for Injectable Drug, Biapenem Sodium for Injectable Drug, and Netupitant/Palonosetron Capsules as the first domestic generics approved for consistency evaluation.
Furthermore, this year, China Pharmaceutical has one biosimilar approved as the first domestic launch: Cetuximab Injectable Drug, whose original product achieved sales of over 3 billion RMB in China’s three major terminals across six major markets in 2024.
Two Class 1 new drugs have also been approved for new indications: Luconshatuo Monoclonal Antibody Injectable Drug (TROP2 ADC) and Tagorimab Injectable Drug (PD-L1 monoclonal antibody).
At Hong Kong Deng Yue Medicine, we regard these achievements — particularly the progress in injectable drugs and other new approvals — as valuable references that deepen our professional insight, strengthen our service capabilities, and enable us to stay ahead of industry trends, ultimately supporting patients and partners with more timely and effective solutions.
